Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments into Endpoints for Regulatory Decision-Making

5 April 2023 – the FDA published draft guidance on patient-focused drug development for industry, FDA staff and other stakeholders. Submit comments by 5 July 2023.

This guidance (Guidance 4) is the fourth in a series of four methodological patient-focused drug development (PFDD) guidance documents that describe how stakeholders (patients, caregivers, researchers, medical product developers, and others) can collect and submit patient experience data and other relevant information from patients and caregivers to be used for medical product development and regulatory decision-making.

Read more online 
Copyright Widler & Schiemann AG 2022. All Rights Reserved. /